ReviewFuture oncology (London, England)2025
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review.
Review in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07707882 (Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor: A Randomized, Open-label Trial
Who cites it
3 citing papers in PubMed.
- Article
- Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion.Advances in therapy · 2026Article
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimTo understand the epidemiology, treatment patterns, economic burden, and humanistic burden of tenosynovial giant cell tumor (TGCT) in the contemporary treatment landscape.
methodsEmbase, MEDLINE, and select conferences were searched to identify studies published between 1 January 2013, and 22/23 August 2023 (database dependent) that included ≥ 20 TGCT patients (≥ 40 for humanistic burden studies). For economic outcomes and treatment patterns, data from 1 January 2008, and later were included.
resultsA total of 35 studies were included. The incidence of TGCT was < 50 cases/million person-years. Surgery was the most common treatment, for which recurrence rates were up to 67%. While quality of life improved after surgery in the absence of recurrence, repeat surgeries for persistent symptoms or recurrent tumors negatively impacted quality of life and inflicted a high economic burden. Systemic therapies were effective and overall improved patient symptoms and quality of life. Treatment was multidisciplinary and involved orthopedic surgeons and medical oncologists as well as supplemental care such as physical therapy.
conclusionTGCT has a high burden, which can be exacerbated by repeat surgeries. Systemic therapies may improve disease and quality of life outcomes in some patients with tumors that are locally advanced or in complicated anatomical locations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.